Tech Company Financing Transactions

Black Diamond Therapeutics Funding Round

Black Diamond Therapeutics closed a $85 million Series C funding round on 12/6/2019. Backers included Boxer Capital, BVF Partners and Casdin Capital.

Transaction Overview

Company Name
Black Diamond Therapeutics
Announced On
12/6/2019
Transaction Type
Venture Equity
Amount
$85,000,000
Round
Series C
Investors

Boxer Capital (Lead Investor)

BVF Partners

Casdin Capital

City Hill Ventures

Deerfield Capital

Invus

Logos Capital

New Enterprise Associates (Ali Behbahani)

Nextech Invest

Perceptive Advisors

RA Capital (Rajeev Shah)

Roche Venture Fund

Versant Ventures (Alex Mayweg)

Wellington Management Company

Proceeds Purpose
The company intends to use the capital to: advance the development of its lead product candidates targeting oncogenic driver mutations of the ErbB kinases in epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), start a combined Phase 1/2 clinical trial of its most advanced product candidate, BDTX-189, in the first half of 2020, continue to expand its earlier stage research programs and proprietary Mutation-Allostery-Pharmacology (MAP) platform to identify and target oncogenic mutations.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
139 Main St. 301
Cambridge, MA 02142
USA
Phone
Undisclosed
Website
www.blackdiamondtherapeutics.com
Email Address
[email protected]
Overview
Black Diamond Therapeutics (Nasdaq: BDTX): A Next-Wave Cancer Precision Medicine Company. Black Diamond Therapeutics has pioneered the development of selective medicines for patients with genetically-defined cancers driven by oncogenes activated by allosteric mutations.
Profile
Black Diamond Therapeutics LinkedIn Company Profile
Social Media
Black Diamond Therapeutics Company Twitter Account
Company News
Black Diamond Therapeutics News
Facebook
Black Diamond Therapeutics on Facebook
YouTube
Black Diamond Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
David Epstein
  David Epstein LinkedIn Profile  David Epstein Twitter Account  David Epstein News  David Epstein on Facebook
Chief Financial Officer
Thomas Leggett
  Thomas Leggett LinkedIn Profile  Thomas Leggett Twitter Account  Thomas Leggett News  Thomas Leggett on Facebook
Chief Operating Officer
Brent Hatzis-Schoch
  Brent Hatzis-Schoch LinkedIn Profile  Brent Hatzis-Schoch Twitter Account  Brent Hatzis-Schoch News  Brent Hatzis-Schoch on Facebook
Chief Scientific Officer
Christopher Roberts
  Christopher Roberts LinkedIn Profile  Christopher Roberts Twitter Account  Christopher Roberts News  Christopher Roberts on Facebook
Executive Vice President
Elizabeth Buck
  Elizabeth Buck LinkedIn Profile  Elizabeth Buck Twitter Account  Elizabeth Buck News  Elizabeth Buck on Facebook
Vice President
Tai-An Lin
  Tai-An Lin LinkedIn Profile  Tai-An Lin Twitter Account  Tai-An Lin News  Tai-An Lin on Facebook
Vice President
Matthew Lucas
  Matthew Lucas LinkedIn Profile  Matthew Lucas Twitter Account  Matthew Lucas News  Matthew Lucas on Facebook
Vice President
Nigel Waters
  Nigel Waters LinkedIn Profile  Nigel Waters Twitter Account  Nigel Waters News  Nigel Waters on Facebook
Vice President
Karsten Witt
  Karsten Witt LinkedIn Profile  Karsten Witt Twitter Account  Karsten Witt News  Karsten Witt on Facebook

 

 

Browse more venture capital transactions:

Prev: 12/6/2019: Uniform Teeth venture capital transaction
Next: 12/6/2019: Bamboo Learning venture capital transaction

 

Share this article

 

News on VC Transactions

We do our best to report on funding rounds that are announced publicly. VC investment data records reported here are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.